activating

TRAP-6 (Thrombin Receptor Activator Peptide 6) 是一种多肽片段，是选择性的蛋白酶激活受体 1 (PAR1) 激动剂，通过凝血酶受体激活人血小板。

Proteasome-activating peptide 1 TFA 是一种肽类蛋白酶体激活剂，能显著增强胰凝乳蛋白酶样蛋白酶体的催化活性，进而提升体外及培养环境中的蛋白质水解效率。此外，Proteasome-activating peptide 1 TFA 还能有效阻止肌萎缩侧索硬化症细胞模型内的蛋白质聚集现象。

Proteasome-activating peptide 1 是一种肽，其作用是提升胰凝乳蛋白酶样蛋白酶体（proteasome）的催化活性，有效增强体外及细胞培养环境下的蛋白质降解效率。此外，该肽能阻止肌萎缩侧索硬化症（Amyotrophic Lateral Sclerosis, ALS）细胞模型中蛋白质的过度聚集。

PAR-2 Activating Peptide acetate (SLIGRL-NH2 acetate)(171436-38-7 free base) 是 Protease-Activated Receptor-2 (PAR-2) 的激动剂。

Sperm-activating peptide 1 is a bioactive chemical.

Macrophage-activating lipopeptide 2 TFA(MALP-2 TFA)是一种二酰基脂肽和TLR-2/TLR-6激动剂,能够激活巨噬细胞等免疫细胞应答，能够上调TNF、IL-6和PGE2来诱导局部炎症。

SLIGRL-NH2 TFA（Protease-Activated Receptor-2 Activating Peptide TFA）作为PAR-2（蛋白酶激活受体-2）的激动剂，具有高度特异性。

PACAP (6-27) (human, ovine, rat) 是一种对PACAP受体具有拮抗作用的化合物，可以抑制犬肾上腺对外源性VIP的反应。此化合物在心血管疾病和神经系统疾病研究中展现出应用潜力。

SLIGRL-NH2 (Protease-Activated Receptor-2 Activating Peptide) 为一种蛋白酶激活受体-2 (PAR-2) 激动剂，具有诱导非组胺能性瘙痒的功能。

PACAP (1-38), a novel neuropeptide isolated from the bovine hypothalamus is more active than vasoactive intestinal peptide (VIP) in stimulating adenylate cyclase (EC50=7 nM). PACAP 1-38 (10-9 M) increased substance P (SP), gastrin releasing peptide (GRP),

PACAP (1-38), human, ovine, rat (Pituitary Adenylate Cyclase Activating Polypeptide 38) 是含有 38 个氨基酸残基的神经肽。它能够结合 PACAP I 型受体(IC50:4 nM)、PACAP II 型受体 VIP1(IC50:2 nM)、PACAP II 型受体 VIP2(IC50:1 nM)。

Rusalatide acetate (TP508 amide acetate) 是一种再生肽，可诱导干细胞再生修复，保护隐窝完整性，减缓辐照引起的胃肠道损伤。

Octapeptide-2 Acetate 作为一种促进毛发生长的活性物质，是一种双层封装的仿生肽，有助于促进细胞生长和迁移。它通过激活毛囊的干细胞来促进头发生长。 它比天然蛋白质更稳定且作用时间更长。

PAR2 (1-6) amide is a synthetic peptide agonist of proteinase-activated receptor 2 (PAR2) that corresponds to residues 1-6 of the amino terminal tethered ligand sequence of human PAR2 and residues 37-42 of the full-length sequence.1It binds to NCTC 2544 cells expressing human PAR2 (Ki= 9.64 μM in a radioligand binding assay) and induces calcium mobilization in the same cells (EC50= 0.075 μM).2PAR2 (1-6) amide (100 μM) reduces colony formation of A549 lung cancer cells.1It induces superoxide production and degranulation in isolated human eosinophils when used at a concentration of 500 μM.3PAR2 (1-6) amide (5 μmol/kg) induces tear secretion in rats when used in combination with amastatin .4 1.Bohm, S.K., Kong, W., Bromme, D., et al.Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2Biochem. J.314(Pt 3)1009-1016(1996) 2.Kanke, T., Ishiwata, H., Kabeya, M., et al.Binding of a highly potent protease-activated receptor-2 (PAR2) activating peptide, [3H]2-furoyl-LIGRL-NH2, to human PAR2Br. J. Pharmacol.145(2)255-263(2005) 3.Miike, S., McWilliam, A.S., and Kita, H.Trypsin induces activation and inflammatory mediator release from human eosinophils through protease-activated receptor-2J. Immunol.167(11)6615-6622(2001) 4.Nishikawa, H., Kawai, K., Tanaka, M., et al.Protease-activated receptor-2 (PAR-2)-related peptides induce tear secretion in rats: Involvement of PAR-2 and non-PAR-2 mechanismsJ. Pharmacol. Exp. Ther.312(2)324-331(2005)

TNF-α antagonist is an exocyclic peptide that mimics the critical TNF-α recognition loop on TNF receptor I complex and, thus, prevents ligand interaction with the receptor. By blocking the TNF receptor ligand contact site, this peptide interferes with both activating receptor activator of NF-κB (RANK) and TNF-α's recruitment and activation of osteoclasts. TNF-α antagonist has been used to block bone resorption in the study of systemic bone loss in rheumatoid arthritis and inflammatory bone destruction.

Pituitary adenylate cyclase-activating peptide (PACAP) (6-27) is a PACAP receptor antagonist with IC50 values of 1,500, 600, and 300 nM, respectively, for rat PAC1, rat VPAC1, and human VPAC2 recombinant receptors expressed in CHO cells. It binds to PACAP receptors on SH-SY5Y and SK-N-MC human neuroblastoma and T47D human breast cancer cells (IC50s = 24.5, 106, and 105 nM, respectively) and inhibits cAMP accumulation induced by PACAP (1-38) (Kis = 457, 102, and 283 nM, respectively, in SH-SY5Y, SK-N-MC, and T47D cells). In vivo, in newborn pigs, PACAP (6-27) (10 μM) inhibits vasodilation of pial arterioles induced by PACAP (1-27) and PACAP (1-38) . It also inhibits PACAP (1-27)-stimulated increases in plasma insulin and glucagon levels and pancreatic venous blood flow in dogs when administered locally to the pancreas at a dose of 500 μg.

PACAP-related peptide (PRP) is an endogenous 29-amino acid peptide that belongs to the secretin/glucagon superfamily of peptides, which includes secretin , glucagon , glucagon-like peptide-1 , GLP-2 , and pituitary adenylate cyclase-activating polypeptide . It is expressed in normal human pancreas and adrenal gland tissue and in some tumors that produce vasoactive intestinal peptide (VIP). PRP (1-29) is secreted by CHO-K1 cells that express human recombinant preproPACAP.

Siamycin I is a tricyclic peptide originally isolated from Streptomyces and has antiviral and antibacterial activities. It is active against laboratory strains and clinical isolates of HIV-1 (ED50s = 0.05-0.45 and 0.89-5.7 μM, respectively), as well as the CBL-20 strain of HIV-2 (ED50 = 0.45 μM), in vitro. Siamycin I inhibits HIV-induced fusion of C8166 T cells with HIV-1-infected CEM-SS cells with an ED50 value of 0.08 μM. It is also active against B. subtilis, M. luteus, and S. aureus (MICs = 1.6-6.3 μg/ml). Siamycin I inhibits autophosphorylation of the E. faecalis quorum sensing kinase FsrC induced by gelatinase biosynthesis-activating pheromone (GBAP).

[Lys8, Lys9]-Neurotensin (8-13) (JMV438) is a Neurotensin analog that elicits analgesic effects by activating the G protein-coupled receptors NTS1 and NTS2. The compound has K i values of 0.33 nM and 0.95 nM for hNTS1 and hNTS2 receptors, respectively.

KRAS G13D peptide, a 25-mer sequence, is derived from the KRAS activating oncogene mutation and serves as an immune potentiator. This peptide possesses immunogenic properties and can be utilized for the development of a KRAS vaccine.

EPQpYEEIPIYL, a phosphopeptide, is a ligand for the Src homology 2 (SH2) domain. It activates members of the Src family, such as Lck, Hck, and Fyn, through the binding interaction with SH2 domains.

ATI-2341 是 C-X-C 趋化因子受体 4 型功能选择性变构激动剂，作为偏向配体有利于 Gα1 激活。它是一种变构激动剂，可激活抑制性异源三聚体 G 蛋白 (Gi) 以促进抑制 cAMP 产生并诱导钙动员。

CR 665 (JNJ 38488502) 是一种外周选择性κ-阿片类激动剂。CR 665可以激活 kappa 阿片受体 EC50值为10.9 nM。CR 665 可用于外周疼痛的研究。

Cyclo(his-pro) 是一种口服具有活力的，结构上与促甲状腺激素释放激素相关的环状二肽。它能够抑制NF-κB 核积累，也能够穿越脑血屏障并影响多种炎症和应激反应。